☆ 4.7 Article

Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation

LEUKEMIA (2023)

Related references

Note: Only part of the references are listed.

Article Hematology

The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia

Clare Sun et al.

Summary: In CLL, oncogenic processes are upregulated in the lymph nodes and in cases with unmutated IGHV region. Single-cell RNA sequencing reveals 3 major cell states in CLL: quiescent, activated, and proliferating. Activated tumor cells are associated with inferior treatment-free survival and the presence of activated CD4+ memory T cells and M2 macrophages in the lymph nodes. Clonal evolution occurs in approximately half of the patients, but is not associated with AICDA expression. However, a T-cell inflamed microenvironment in the lymph nodes is associated with clonal stability.

BLOOD ADVANCES (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Timothy A. Yap et al.

Summary: Despite being a rational anticancer strategy, targeting OXPHOS with inhibitors has not yet shown clinical benefit. Two phase I trials of IACS-010759, a potent and selective complex I inhibitor, were conducted in patients with relapsed/refractory acute myeloid leukemia and advanced solid tumors. However, dose-limiting toxicities and limited antitumor activity were observed, leading to the discontinuation of both trials.

NATURE MEDICINE (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome

Erin M. Parry et al.

Summary: Richter syndrome (RS), an aggressive malignancy that arises from chronic lymphocytic leukemia (CLL), has been studied to understand its genetic mechanisms. Through computational analysis of CLL-RS whole-exome sequencing data, specific somatic driver mutations, recurrent copy-number alterations, and chromosomal abnormalities were identified in RS cells. The study also revealed distinct molecular subtypes of RS and the potential use of cell-free DNA analysis for early diagnosis and monitoring.

NATURE MEDICINE (2023)

Add to Collection

Review Oncology

The Effect of Oxidative Phosphorylation on Cancer Drug Resistance

Ziyi Zhao et al.

Summary: Drug resistance in cancer patients significantly impacts their survival and quality of life, but targeting oxidative phosphorylation (OXPHOS) can eliminate cancer stem cells and delay the acquisition of drug resistance. Recent studies have shown that OXPHOS inhibitors can improve treatment responses to anticancer therapy in specific cancers, while also playing a complex role in cancer drug resistance.

CANCERS (2023)

Add to Collection

Letter Hematology

Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models

Elisa ten Hacken et al.

BLOOD ADVANCES (2023)

Add to Collection

Article Hematology

Richter syndrome: Novel insights into the biology of transformation

Erin M. Parry et al.

BLOOD (2023)

Add to Collection

Review Oncology

Emerging Therapies for the Management of Richter Transformation

Elizabeth Smyth et al.

Summary: Richter transformation (RT) is the development of an aggressive lymphoma in patients with underlying chronic lymphocytic leukemia/small lymphocytic lymphoma. Standard therapies have poor response rates, but recent advancements in understanding the biology of RT and the emergence of targeted therapies may lead to improved outcomes.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Biology

SF3B1 mutation-mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia

Irene Lopez-Oreja et al.

Summary: In this study, the researchers used deep RNA sequencing data to analyze CLL tumor samples and SF3B1 wild-type and K700E-mutated CLL cell lines. They identified protein pre-mRNA features and cryptic 39 splice site events associated with SF3B1 mutation. They also demonstrated the cytotoxic effects of the splicing modulator H3B-8800 in CLL samples and SF3B1-mutated cell lines, and its potential therapeutic use in combination with the BCL2 inhibitor venetoclax in CLL.

LIFE SCIENCE ALLIANCE (2023)

Add to Collection

Article Oncology

In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities

Elisa ten Hacken et al.

Summary: Using CRISPR-Cas9 editing in mice, researchers simulated the transformation of chronic lymphocytic leukemia (CLL) into large cell lymphoma and uncovered the role of key gene mutations.

BLOOD CANCER DISCOVERY (2023)

Add to Collection

Article Oncology

Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma

Giulio Donati et al.

Summary: MYC activity is closely correlated with gene expression signatures related to oxidative phosphorylation in DLBCL, sensitizing B cells to the ETC complex I inhibitor IACS-010759. The combination of BCL2 inhibitor venetoclax and IACS-010759 showed synergy in DHL with concurrent activation of MYC and BCL2, while in BCL2-negative lymphoma cells, the Mcl-1 inhibitor S63845 potentiated killing by IACS-010759. This suggests a novel therapeutic approach against aggressive, MYC-associated DLBCL variants.

MOLECULAR ONCOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia

Natalia Baran et al.

Summary: The study reveals that T-ALL is commonly driven by activating mutations in NOTCH1, which directly relates to elevated OxPhos gene expression. Inhibition of OxPhos disrupts leukemia cell growth and induces metabolic reprogramming into glutaminolysis. Combining OxPhos blockade with inducible knock-down of glutaminase shows synthetic lethality in NOTCH1-mutated T-ALL mice.

NATURE COMMUNICATIONS (2022)

Add to Collection

Review Oncology

Biology and Treatment of Richter Transformation

Adalgisa Condoluci et al.

Summary: Richter transformation (RT) is an aggressive lymphoma that develops on a background of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with a poor prognosis. Recent developments in preclinical models and genetic rationale-based therapeutic strategies aim to improve patient outcomes in this setting.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Hematology

Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells

J. A. C. van Bruggen et al.

Summary: Patients with chronic lymphocytic leukemia (CLL) exhibit reduced functionality of CD4 T cells due to metabolic restrictions imposed by CLL cells. Treatment with venetoclax plus obinutuzumab can restore T-cell activation and switch to glycolysis, as well as improve T-cell proliferation.

BLOOD ADVANCES (2022)

Add to Collection

Article Genetics & Heredity

Molecular map of chronic lymphocytic leukemia and its impact on outcome

Binyamin A. Knisbacher et al.

Summary: This study identifies genetic drivers and molecular subtypes associated with clinical outcomes in chronic lymphocytic leukemia (CLL) through genomic, transcriptomic, and epigenomic analysis. The findings provide fresh insights into the oncogenesis and prognostication of CLL.

NATURE GENETICS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Detection of early seeding of Richter transformation in chronic lymphocytic leukemia

Ferran Nadeu et al.

Summary: By analyzing the genome, epigenome, and transcriptome of CLL cases developing RT, this study reveals the presence of minute subclones with RT features at CLL diagnosis and identifies potential therapeutic targets through OXPHOS inhibition.

NATURE MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

MYC sensitises cells to apoptosis by driving energetic demand

Joy Edwards-Hicks et al.

Summary: MYC activation enhances global transcription and translation, creating a metabolic demand. Glutamine limitation leads to an imbalance of metabolic supply and demand, sensitising cells to apoptosis. Glutamine supports the viability of MYC-overexpressing cells through TCA cycle energetics rather than biosynthetic mechanism.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Hematology

Macrophage- and BCR- but not TLR-derived signals support the growth of CLL and Richter Syndrome murine models in vivo

Claudio Martines et al.

BLOOD (2022)

Add to Collection

Review Oncology

Towards precision oncology with patient-derived xenografts

Eugenia R. Zanella et al.

Summary: Clinical research requires support from preclinical models that take into consideration the biology and genetics of human cancers, such as patient-derived xenograft (PDX) models. The authors of this Review discuss how PDX models have been used in the past decade for precision oncology and present emerging approaches that could broaden the application of these models.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

Add to Collection

Article Hematology

Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia

Jenny Klintman et al.

Summary: The transformation of chronic lymphocytic leukemia into high-grade B-cell lymphoma, known as Richter syndrome, involves specific genetic mutations affecting pathways such as DNA damage response (DDR) and MAPK. Whole-genome sequencing and RNA expression profiling can help identify novel genomic correlates and pathways implicated in this transformation, offering potential therapeutic targets. The study emphasizes the importance of integrated analysis in predicting the genetic changes driving the progression from CLL to RS.

BLOOD (2021)

Add to Collection

Article Hematology

IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics

Ferran Nadeu et al.

Summary: The B-cell receptor (BCR) signaling is crucial for chronic lymphocytic leukemia (CLL) biology, with IGLV3-21-expressing B cells potentially acquiring a single point mutation (R110) triggering autonomous BCR signaling. Epigenetic studies have identified 3 CLL subtypes, with IGLV3-21(R110) CLL defining a subgroup with specific biological features and an unfavorable prognosis independent of IGHV mutational status and epigenetic subtype.

BLOOD (2021)

Add to Collection

Article Hematology

ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models

Tiziana Vaisitti et al.

Summary: The Richter syndrome (RS) is a transformation of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma, with limited treatment options and high fatality rates. Targeting the receptor tyrosine kinase-like orphan receptor 1 (ROR1) with the antibody-drug conjugate (ADC) VLS-101 has shown promising results in RS patient-derived xenografts, indicating the therapeutic potential of this approach for hematological cancers. A phase 1 clinical trial of VLS-101 (NCT03833180) is currently ongoing in patients with RS and other hematological malignancies.

BLOOD (2021)

Add to Collection

Review Hematology

Understanding CLL biology through mouse models of human genetics

Elisa ten Hacken et al.

Summary: Rapid advances in large-scale sequencing studies have revealed the genetic heterogeneity of CLL, while mouse models have become powerful tools for studying B-cell biology and new therapeutics. Genetic engineering technologies have enabled the creation of novel mouse models that provide deeper insights into disease evolution and therapy responses, contributing valuable platforms for functional genomic analyses and treatment studies in CLL and RS.

BLOOD (2021)

Add to Collection

Article Oncology

BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma

Warren Fiskus et al.

Summary: This study reports the characteristics of three newly established patient-derived xenograft models of RT-DLBCL, including genetic alterations, gene expressions, and drug sensitivity. The findings suggest potential novel therapies for RT-DLBCL, including BET protein inhibitors.

LEUKEMIA (2021)

Add to Collection

Article Immunology

A Detailed Analysis of Parameters Supporting the Engraftment and Growth of Chronic Lymphocytic Leukemia Cells in Immune-Deficient Mice

Piers E. M. Patten et al.

Summary: The patient-derived xenograft models of chronic lymphocytic leukemia (CLL) can be established using highly immunodeficient animals, allowing the analysis of primary tumor cells in vivo. By pre-activating CLL-derived T lymphocytes in vitro, a reliable system for primary CLL cell growth within a fully autologous system can be achieved. The growth kinetics and degree of anatomic localization of CLL B and T cells are significantly influenced by the route of administration, with different patterns observed between intravenous and intraperitoneal delivery. This model provides a powerful tool for evaluating CLL biology and novel therapeutics in vivo.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Hematology

Synergistic efficacy of the dual PI3K-d/g inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

Andrea Iannello et al.

Summary: This study demonstrates the efficacy of dual targeting of PI3K-delta/gamma and Bcl-2 in Richter syndrome (RS), with combination therapy being more effective than monotherapy. Different RS cells show variable responses to Duv and Ven, but the Duv/Ven combination shows the best tumor growth inhibition.

BLOOD (2021)

Add to Collection

Article Hematology

B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation

Supriya Chakraborty et al.

Summary: BCR signals play a direct role in driving CLL cell proliferation by inducing both positive and negative regulators of the cell cycle. Genetic lesions that downregulate cell-cycle inhibitors like CDKN1A, CDKN2A, and CDKN2B, as well as TP53, lead to more aggressive disease and spontaneous proliferation. Furthermore, inactivating lesions in CDKN2A, CDKN2B, and TP53 frequently co-occur in Richter syndrome, and BCR stimulation with such lesions can induce proliferation.

BLOOD (2021)

Add to Collection

Article Multidisciplinary Sciences

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma

Shaojun Zhang et al.

Summary: This study investigates the mechanisms driving resistance to treatment in mantle cell lymphoma (MCL) by analyzing the cellular and molecular heterogeneity within patients using single-cell sequencing. The researchers found temporal activation of cancer hallmark pathways and acquisition of 17q in refractory MCL, leading to upregulation of BIRC5/survivin expression. They demonstrate that targeting BIRC5 results in effective tumor inhibition in preclinical models and also identify changes in the tumor microenvironment in refractory MCL, including decreased CD8+ T cells and aberrant cell-to-cell communication networks.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Oncology

Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome

Yucai Wang et al.

Summary: Compared to CLL patients, RS patients showed higher expression of PD-L1 in histiocytes and dendritic cells, as well as PD1 in neoplastic B cells in nodal tissue, along with increased infiltration of FOXP3-positive T cells and CD163-positive macrophages. Additionally, peripheral blood T-cell receptor clonality was significantly lower in RS patients, indicating a more diverse T-cell population in RS compared to CLL. These findings suggest that CLL and RS have distinct immune signatures that may impact immunotherapy efficacy.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Editorial Material Pharmacology & Pharmacy

Advantages and disadvantages of mouse models of chronic lymphocytic leukemia in drug discovery

Heribert Playa-Albinyana et al.

EXPERT OPINION ON DRUG DISCOVERY (2021)

Add to Collection

Article Oncology

Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia

Claudie Bosc et al.

Summary: Therapy resistance in AML is linked to high mitochondrial oxidative phosphorylation identified by MitoScore. Targeting mitochondrial metabolism can delay AML relapse, highlighting the central role of mitochondrial adaptation in AML therapy.

NATURE CANCER (2021)

Add to Collection

Article Oncology

Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia

Junyan Lu et al.

Summary: Huber and colleagues identified a proliferative drive axis involving mTOR, MYC, and OXPHOS metabolic activity in CLL, which is associated with disease heterogeneity and outcome. Their multi-omic analysis revealed a biological axis of heterogeneity strongly linked to clinical behavior and orthogonal to known biomarkers. The CLL proliferative drive axis was validated in multiple cohorts and is a key determinant of disease outcome.

NATURE CANCER (2021)

Add to Collection

Review Pathology

Genomic and Epigenomic Alterations in Chronic Lymphocytic Leukemia

Ferran Nadeu et al.

ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 15, 2020 (2020)

Add to Collection

Review Oncology

Applications of patient-derived tumor xenograft models and tumor organoids

Go J. Yoshida

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling

Palash C. Maity et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Add to Collection

Editorial Material Hematology

Leukemic phase of Richter transformation: A mimic of acute myeloid leukemia that responded to Ibrutinib monotherapy

Hui Liu et al.

AMERICAN JOURNAL OF HEMATOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

SynergyFinder 2.0: visual analytics of multi-drug combination synergies

Aleksandr Ianevski et al.

NUCLEIC ACIDS RESEARCH (2020)

Add to Collection

Review Hematology

Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies

Julio Delgado et al.

HAEMATOLOGICA (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting the Mitochondrial Metabolic Network: A Promising Strategy in Cancer Treatment

Luca Frattaruolo et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection

Article Oncology

Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation

Fangbing Liu et al.

CANCERS (2020)

Add to Collection

Article Oncology

Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development

Nadja Zaborsky et al.

LEUKEMIA (2019)

Add to Collection

Article Cell Biology

Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma

Liang Zhang et al.

SCIENCE TRANSLATIONAL MEDICINE (2019)

Add to Collection

Review Hematology

Biology and treatment of Richter syndrome

Davide Rossi et al.

BLOOD (2018)

Add to Collection

Article Oncology

Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses

Tiziana Vaisitti et al.

CANCER RESEARCH (2018)

Add to Collection

Article Biochemistry & Molecular Biology

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Jennifer R. Molina et al.

NATURE MEDICINE (2018)

Add to Collection

Article

Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells

Hima V. Vangapandu et al.

Oncotarget (2018)

Add to Collection

Article Hematology

Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling

June H. Myklebust et al.

BLOOD (2017)

Add to Collection

Letter Hematology

Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors

Kah-Lok Chan et al.

BRITISH JOURNAL OF HAEMATOLOGY (2017)

Add to Collection

Article Hematology

Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor

Tiziana Vaisitti et al.

HAEMATOLOGICA (2017)

Add to Collection

Article Multidisciplinary Sciences

The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition

Gabriele Varano et al.

NATURE (2017)

Add to Collection

Article Multidisciplinary Sciences

Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia

Claudia Minici et al.

NATURE COMMUNICATIONS (2017)

Add to Collection

Article Oncology

Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

Thomas Farge et al.

CANCER DISCOVERY (2017)

Add to Collection

Article Hematology

Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor

Tiziana Vaisitti et al.

HAEMATOLOGICA (2017)

Add to Collection

Article Oncology

Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia

Lili Wang et al.

CANCER CELL (2016)

Add to Collection

Article Multidisciplinary Sciences

Non-coding recurrent mutations in chronic lymphocytic leukaemia

Xose S. Puente et al.

NATURE (2015)

Add to Collection

Article Multidisciplinary Sciences

Mutations driving CLL and their evolution in progression and relapse

Dan A. Landau et al.

NATURE (2015)

Add to Collection

Article Biochemistry & Molecular Biology

Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model

Bhagwan Yadav et al.

COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2015)

Add to Collection

Article Genetics & Heredity

Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia

Marta Kulis et al.

NATURE GENETICS (2012)

Add to Collection

Article Multidisciplinary Sciences

B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia

Xiao-jie Yan et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)

Add to Collection

Article Multidisciplinary Sciences

Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression

R Bichi et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.